Dr. Michael E. Albo, MD

Dr. Albo practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Albo's NPI, 1912938499, was assigned on July 5, 2006. Dr. Albo graduated from Spencer Fox Eccles School of Medicine in 1988. Dr. Albo holds California license G81920.

Dr. Albo's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Albo's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Albo is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Albo practices. Vendor and product names are available with a free account.

Urology is Dr. Albo's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Albo is board certified in female pelvic medicine and reconstructive surgery by the American Board of Urology. Dmand AI has Dr. Albo's licenses on file in 2 states: California and Illinois.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), kidney stone disease, pelvic prolapse, prostate cancer, urinary endoscopy and urine flow blockage among the conditions Dr. Albo treats.

CMS data shows 3,814 Medicare services from Dr. Albo across 18 procedure codes in 2024, for 402 Medicare patients. Medicare paid $76,229 for them.

CMS counts 402 Medicare patients who saw Dr. Albo in 2026. The largest group is 75 to 84, with 145 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 30% are also on Medicaid. Their average risk score is 2.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Albo's median patient age at 65, with 48% women.

In 2026, Dr. Albo wrote 585 Medicare Part D claims for 205 patients. 58% of them were for generic drugs. CMS names the drug for 468 of them, across 10 drugs with 11 or more claims each, at $205,149 in total drug cost. In 2023, CMS named 651 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Albo for performance year 2026, reported as part of a group. Dr. Albo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Albo as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 34 papers to Dr. Albo, published from 2007 to 2020. 2012 was the busiest year, with 5. The most frequent topics are Urinary Incontinence, Stress, Urodynamics and Suburethral Slings. Dr. Albo has published most often in J Urol. Dr. Albo's most frequent co-authors are Linda Brubaker, MD, Stephen R. Kraus, MD and Toby Chai, MD.

Dmand AI links Dr. Albo to 1 clinical trial. Conditions studied include Urinary Incontinence, Stress and Urinary Incontinence.

CMS Open Payments shows 113 general payments to Dr. Albo from 27 drug and device companies from 2016 to 2025. Grants make up the largest share, 56% of the total. Boston Scientific Corporation paid the most, $4,050.

Dmand AI lists 5 awards for Dr. Albo, most recently CMS Stage 1 EHR in 2013.

Dr. Albo graduated from Spencer Fox Eccles School of Medicine in 1988. Dr. Albo is a member of ACS.

Dr. Albo is in network with 8 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.